Regencell Bioscience (RGC) : 4-year performance

Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. It seeks the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder and autism spectrum disorder. 

• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic
• Full Time Employees: 12
• Incorporated in 2014 
• Headquartered in Causeway Bay, Hong Kong
• https://www.regencellbioscience.com

IPO: July 16, 2021